Do you want to read an article? Please log in or register.
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274
Genitourinary Cancer
Related content
SPECIAL REPORT
Genitourinary Cancer
EAU Annual Congress 2024: adjuvant therapy for high-risk muscle-invasive urothelial carcinoma with PD-L1 expression ≥ 1
Genitourinary Cancer
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
N Engl J Med
Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, Teo MY, Sweis RF, Geynisman DM, Grivas P, Chatta G, Reichert ZR, Kim JW, Bilen MA, McGregor B, Singh P, Tripathi A, Cole S, Simon N, Niglio S, Ley L, Cordes L, Srinivas S, Huang J, Odegaard M, Watt C, Petrylak D, Hoffman-Censits J, Wen Y, Hahn O, Mitchell C, Tan A, Streicher H, Sharon E, Moon H, Woods M, Halabi S, Perez Burbano G, Morris MJ, Rosenberg JE
doi: 10.1056/NEJMoa2401726
COMMENTED
Genitourinary Cancer
Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
BJU Int
Scilipoti P, Longoni M, de Angelis M, Zaurito P, Massiet A, Dutto D, Soria F, Álvarez-Maestro M, Bazán AA, Pradere B, Klatte T, Contieri R, Hurle R, Krajewski W, Subiela JD, Pichler R, Szostek A, Marcq G, Elena JLR, Aranda J, Gontero P, Rouprêt M, Shariat SF, Necchi A, Montorsi F, Briganti A, Xylinas E, Moschini M, EuroGemDoce Study Group Collaborators, European Association of Urology ‐ Young Academic Urologists (EAU‐YAU), Urothelial Carcinoma Working Group
doi: 10.1111/bju.16645
Genitourinary Cancer
Predicting response to intravesical BCG in high-risk non-muscle invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12 center cohort
J Urol
Lotan Y, Krishna V, Abuzeid WM, Launer B, Chang SS, Krishna V, Shingi S, Gordetsky JB, Gerald T, Woldu S, Shkolyar E, Hayne D, Redfern A, Spalding L, Stewart C, Eyzaguirre E, Imtiaz S, Narayan VM, Packiam VT, O'Donnell MA, Li R, Baekelandt L, Joniau S, Zuiverloon T, Fernandez MI, Schultz M, Hensley PJ, Allison D, Taylor JA, Hamza A, Kamat A, Nimgaonkar V, Sonawane S, Miller DL, Watson D, Vrabac D, Joshi A, Shah JB, Williams SB
doi: 10.1097/JU.0000000000004278
Genitourinary Cancer
PD-L1 expression and correlation with outcome in muscle-invasive and metastatic urothelial carcinoma: review and critical discussion
Front Oncol
El Saadany T, Lorch A, Milowsky MI, Vogl UM, Cathomas R
doi: 10.3389/fonc.2024.1427452
Genitourinary Cancer
Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial
BJU Int
Conroy S, Jubber I, Noon AP, Rosario DJ, Griffin J, Morgan S, Hubbard R, Kennish S, Mitchell S, Venugopal S, Linton K, Rajasundaram R, Hussain SA, Catto JWF
doi: 10.1111/bju.16516
COMMENTED
Genitourinary Cancer
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Ann Oncol
Tannir NM, Albigès L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER, Porta C, George S, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Grünwald V, Rini BI, Jiang R, Desilva H, Federov V, Lee CW, Motzer RJ
doi: 10.1016/j.annonc.2024.07.727
ELCC 2024
Lung, Respiratory and Thoracic Cancer
LBA2. CheckMate 77T: Improved efficacy with perioperative nivolumab in patients with resectable NSCLC
Lymphoma
Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis
Haematologica
Tolley ER, Lewinter C, Pedersen LM, Nielsen TH
doi: 10.3324/haematol.2023.284281